Everything You Need to Scale Innovation

20 Frameworks, Startup Intelligence & More!
DOWNLOAD YOUR 40 PAGE WHITEPAPER

Executive Summary: Genomics Industry Report [2026]

  • Industry Growth Overview: The genomics industry grows at a 4.31% annual rate. The global market is projected to expand from USD 50.1 billion in 2025 to USD 304.8 billion by 2035.
  • Manpower & Employment Growth: The sector employs over 1.2 million professionals worldwide, with 480+ new employees added in the last year.
  • Patents: More than 192 600 patents filed by about 48 900 applicants.
  • Global Footprint: The USA, UK, India, Canada, and Germany emerge as the national hub centers with key city hubs including London, Cambridge, New York City, San Francisco, and San Diego.
  • Investment Landscape: The industry closed 14 100+ funding rounds, supported by a broad financing base of 11 530+ investors.
    Top Investors: The top investors have deployed more than USD 23 billion into genomics. Leading contributors include Bayer (USD 3.7B, 9 companies), Sartorius (USD 2.5B), and Genentech (USD 2.5B), among others.
  • Startup Ecosystem: Five innovative startups in this sector include Ellis Bio (epigenomics kits), Lucid Genomics (AI-powered genome analysis software), Genorare (rare disease diagnostics platform), OutSee (phenotype prediction AI engine), and Adalid Sciences (lipid nanoparticle delivery systems).

 

 

Methodology: How we created this Genomics Report

This report is based on proprietary data from our AI-powered StartUs Insights Discovery Platform, which tracks 9 million global companies, 20K+ technologies and trends, as well as 150M patents, news articles, and market reports.

This data includes detailed firmographic insights into approximately 9 million startups, scaleups, and tech companies. Leveraging this exhaustive database, we provide actionable insights for startup scouting, trend discovery, and technology landscaping.

For this report, we focused on the evolution of genomics over the past 5 years, utilizing our platform’s trend intelligence feature. Key data points analyzed include:

  • Total Companies working in the sector
  • News Coverage and Annual Growth
  • Market Maturity and Patents
  • Global Search Volume & Growth
  • Funding Activity and Top Countries
  • Subtrends within the genomics industry

Our data is refreshed regularly, enabling trend comparisons for deeper insights into their relative impact and importance.

Additionally, we reviewed trusted external resources to supplement our findings with broader market data and predictions, ensuring a reliable and comprehensive overview of the genomics market.

What Data is used to create this Genomics Market Outlook?

Based on data provided by the StartUs Insights Discovery Platform, we observe that the genomics market stands out in the following categories relative to the 20K+ technologies and trends we track.

These categories provide a comprehensive overview of the market’s key metrics and inform the future direction of the market.

  • News Coverage & Publications: The genomics industry received more than 4810 news mentions and publications in the last year.
  • Funding Rounds: The sector closed 14 100+ funding rounds linked to genomics companies, which reflects active investor participation across research, biotechnology, and clinical innovation.
  • Manpower: It employs over 1.2 million workers worldwide, with more than 480 new employees added in the last year.
  • Patents: Companies operating in genomics have filed 192 600+ patents.
  • Yearly Global Search Growth: Global search activity for genomics increased by 131.94% year over year.

Explore the Data-driven Genomics Market Report for 2026

The genomics sector advances as innovations in sequencing technologies, computational biology, and precision medicine reshape global healthcare and research ecosystems. Our database records 1235+ startups within a broader pool of 13 630+ companies active in the genomics landscape.

With a yearly industry growth rate of 4.31%, the field is expanding steadily with rising demand for personalized therapies, early disease detection, and advanced biomolecular analysis.

Moreover, companies have filed for more than 192 600 patents, which reflects the R&D activity across gene editing, bioinformatics, biomarker discovery, synthetic biology, and next-generation sequencing platforms.

Supporting this innovation pipeline is a global workforce of 1.2 million professionals, with 480+ new employees added in the last year.

The USA, UK, India, Canada, and Germany lead as the national hubs with significant investments and advances in biomedical research, life sciences infrastructure, and clinical genomics.

On the city level, London, Cambridge, New York City, San Francisco, and San Diego emerge as major centers where research institutions, startups, and biotech companies converge.

A Snapshot of the Global Genomics Market

The industry is expected to increase from USD 50.1 billion in 2025 to USD 304.8 billion by 2035 with a compound annual growth rate (CAGR) of 19.8% from 2025 to 2035.

 

 

With a yearly industry growth rate of 4.31%, the sector demonstrates steady momentum. The sector includes 1235+ startups contributing to this progress with an innovation ecosystem spanning gene editing, multi-omics analysis, and clinical genomics.

The market was divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these, North America led the global genomics market in 2024, holding the largest share at 42.65%.

 

 

Innovation activity remains a core engine of growth. More than 48.9K applicants have filed for more than 192.6K patents, filed by 48,900 applicants.

Further, a 2.30% yearly patent growth rate indicates sustained advancement to support the long-term evolution of tools and technologies that underpin precision medicine.

Patent leadership is concentrated across two major scientific powerhouses. The USA, with 53.8K patents, remains the global leader in genomics innovation. China follows with 46.1K patents.

Explore the Funding Landscape of the Genomics Market

The average investment value of USD 49.1 million per round reflects strong confidence in both foundational research platforms and commercially advancing therapeutic and diagnostic technologies.

More than 14 100 funding rounds are recorded, which span seed-stage innovation, growth-stage biotech ventures, and large-scale clinical development programs.

This momentum is supported by a broad network of over 11 530 investors. It includes venture capital firms, corporate biotech funds, pharmaceutical companies, and institutional investors specializing in life sciences. These investors have funded more than 3330 companies.

Who is Investing in the Genomics Market?

The top investors in the genomics sector have invested more than USD 23 billion.

Top Genomics Innovations & Trends

Discover the emerging trends in the genomics market along with their firmographic details:

 

Next-Generation Sequencing (NGS)

This segment remains one of the largest and most established trends within the genomics sector. With 1565+ companies and 141.6K employees, including 80+ new hires in the past year, NGS drives high-throughput genomic analysis across research, diagnostics, and clinical applications.

Its 4.64% annual trend growth rate reflects steady expansion as sequencing becomes integral to disease detection, treatment planning, ancestry insights, and population-scale genomic programs.

Functional Genomics

It gains traction as researchers and biotech companies deepen their exploration of gene function, regulatory networks, and disease mechanisms. This domain includes 230+ companies employing 27.1K people, with 10+ new employees added in the last year.

An annual growth rate of 6.43% highlights rising investment in clustered regularly interspaced short palindromic repeats (CRISPR)-based screens, single-cell technologies, pathway mapping, and high-throughput assay platforms.

Computational Genomics

This represents one of the fastest-growing areas in the sector, driven by the expanding scale of genomic datasets and the need for advanced analytics. With 72 companies and 1800 employees, including 1 new hire in the past year, the segment demonstrates an annual growth rate of 12.68%.

This growth is increased by innovations in algorithm development, machine learning, cloud-based genomic processing, and integrated multi-omics analysis.

5 Top Examples from 1235+ Innovative Genomics Startups

The five innovative startups showcased below are picked based on data including the trend they operate within and their relevance, founding year, funding status, and more. Book a demo to find promising startups, emerging trends, or industry data specific to your company’s needs and objectives.

Ellis Bio offers Epigenomic Kits

US-based startup Ellis Bio develops SuperMethyl Fast and SuperMethyl Max, two bisulfite conversion kits that strengthen DNA methylation analysis across research and clinical workflows.

SuperMethyl Fast performs C-to-U conversion through an optimized rapid-reaction chemistry by using ready-to-apply reagents that minimize handling and maintain conversion efficiency.

It supports a broad input range, preserves high DNA recovery, and integrates into downstream applications such as polymerase chain reaction (PCR), microarrays, and next-generation sequencing.

In contrast, SuperMethyl Max uses ultra-mild bisulfite chemistry to preserve DNA integrity during conversion and enables accurate methylation profiling from inputs as low as 100 pg.

It achieves high C-to-T conversion, maintains longer fragment lengths, and ensures uniform guanine-cytosine (GC) coverage across promoter and GC-rich regions.

Lucid Genomics builds AI-powered Genome Analysis Software

German startup Lucid Genomics develops an AI-driven platform that unifies detection, prioritization, and interpretation of genetic variants across individual, family, and cohort analyses.

It processes complete genomic data by examining both coding and non-coding regions, extracting information from every base of the DNA sequence, and scoring mutations according to their potential pathogenicity.

Lucid Genomics deploys specialized AI models for variant detection and prioritization to reduce structural-variant false positives. Moreover, it achieves higher accuracy in ranking pathogenic mutations through its disease-agnostic scoring system and regulatory-aware expert layer.

Further, the platform evaluates genes across different samples in less time, while filtering noisy short-read datasets to reduce false positives.

Also, it detects the full spectrum of variants, including single-nucleotide variants (SNVs), insertions and deletions (InDels), structural variants, and repeat expansions.

It deepens interpretation through multi-omics integration by combining epigenetic signals, gene expression data, and 3D genome architecture to highlight biologically relevant mutations and presents results through integrated visualizations that simplify hypothesis generation.

Genorare makes a Rare Disease Diagnosis Platform

Dutch startup Genorare develops a privacy-preserving diagnostic platform that identifies rare diseases by combining encrypted data processing with advanced clinical reasoning models.

It begins by gathering genomic sequences, electronic health records (EHR) information, and laboratory results directly from the patient’s clinical environment. With this, it encrypts each dataset at the source through a unique public-private key pair so that no unprotected information leaves the originating system.

The platform then performs computation on this encrypted content using homomorphic techniques that allow pattern detection, phenotype mapping, and literature-driven inference without exposing the underlying records.

During this stage, structured phenotype ontologies and language-based analysis extract clinical meaning from medical notes to reveal candidate disorders while maintaining strict confidentiality.

Once processing concludes, the encrypted results are returned to the clinician, who decrypts them locally with the patient’s private key to view prioritized risk scores and actionable insights that support more precise decision-making.

OutSee offers a Phenotype Prediction AI Engine

UK-based startup OutSee develops Nomaly, a predictive genomics engine that interprets a single genome by modeling the biological mechanisms that drive disease rather than relying on association-based signals.

Nomaly analyzes variation across coding and non-coding regions to infer functional effects, while capturing multi-variant influences and cooperative interactions that shape complex traits. This supports consistent performance across small and large cohorts.

Also, it groups patients according to mechanistic similarity to reveal patterns that remain hidden when methods depend on known variants or established correlations.

Adalid Sciences provides a Lipid Nanoparticle Delivery System

Czech Republic-based startup Adalid Sciences develops structurally novel lipid nanoparticles to deliver nucleic acid therapeutics.

The startup synthesizes ionizable lipidoids with an adamantane-based architecture and evaluates their performance through detailed biophysical characterization and in vivo studies.

Moreover, it assists in protein replacement, monoclonal antibody expression, vaccines, RNA interference, and gene editing.

Gain Comprehensive Insights into Genomics Trends, Startups, and Technologies

The report highlights a genomics industry advancing with sustained innovation, rising data generation, and accelerating convergence with computational technologies.

Companies are advancing sequencing, diagnostics, and therapeutic development, while pushing innovations in gene editing, personalized medicine, and bioinformatics.

The sector attracts significant investment as precision health becomes a global priority. These developments highlight new possibilities for clinicians, researchers, and biotech organizations to unlock biological insights and improve human health outcomes.

Get in touch to explore 1235+ startups and scaleups, as well as all market trends impacting genomics companies.